Analysts at Credit Suisse have upgraded this pharmaceutical company’s shares to an outperform rating from neutral with an increased price target of $1.00. The broker has made the move after assessing the market opportunity for two news products Mayne Pharma plans to release this year. Furthermore, the broker has suggested that investors view any earnings season share price weakness as a buying opportunity.
Can MYX become Blackmores of generics, page-160
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.03 |
Change
-0.190(4.50%) |
Mkt cap ! $342.8M | |||
| Open | High | Low | Value | Volume |
| $4.10 | $4.22 | $4.02 | $1.235M | 303.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $4.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.04 | 164 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |